Unit of Urology, Maternal-Infantile and Urological Sciences Department, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy -
Unit of Urology, Maternal-Infantile and Urological Sciences Department, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy.
Minerva Urol Nephrol. 2022 Jun;74(3):255-264. doi: 10.23736/S2724-6051.21.04308-1. Epub 2021 Jun 22.
Proteinuria is considered both a known marker for the severity of chronic kidney disease (CKD) and a robust predictor of future renal function and cardiovascular morbidity and mortality in a general population. The urological community has long overlooked proteinuria as a marker of renal function. Recently, the American Urological Association (AUA) clinical practice guideline addressed this issue and suggested introducing proteinuria assessment prior to kidney cancer surgery. The aim of this systematic review was to provide evidence of proteinuria as a predictor of renal function impairment and survival outcomes after kidney surgery for renal tumors.
A systematic search was performed by using three search engines (PubMed, Embase, and Web of Science) from January 2010 to November 2020. Study selection followed the PRISMA guidelines. After screening, ten articles and abstracts fully compatible with the PICOS were included in this systematic review.
Overall, a total of 11,705 patients who underwent partial nephrectomy (PN) or radical nephrectomy (RN) were analyzed. When used as a binomial variable, proteinuria prior to surgery was detected from 10% to 33% of patients. Relying on both proteinuria and estimated glomerular filtration rate (eGFR) in the assessment of renal function yielded up to 33% higher rates of patients with preoperative renal impairment. Moreover, proteinuria increased the risk of long-term renal impairment after PN and RN as well as patients with preoperative proteinuria undergoing PN exhibited a greater risk of postoperative acute kidney injury (AKI). Among eligible studies, proteinuria was associated with diabetes, obesity, metabolic syndrome, hypertension and cardiovascular disease. Finally, proteinuria was an independent predictor of overall mortality, but not of cancer-specific mortality.
Proteinuria yields a prognostic power beyond that provided by estimated glomerular filtration rate (eGFR) among patients undergoing renal cancer surgery, supporting its introduction in the preoperative assessment of renal function. However, well-designed multicenter prospective studies would be necessary to corroborate these results and provided urological community with high-grade recommendation for clinical practice.
蛋白尿不仅被认为是慢性肾脏病 (CKD) 严重程度的已知标志物,而且在普通人群中也是未来肾功能以及心血管发病率和死亡率的强有力预测指标。长期以来,泌尿科医生一直忽略了蛋白尿作为肾功能标志物的作用。最近,美国泌尿外科学会 (AUA) 临床实践指南解决了这个问题,并建议在肾癌手术前进行蛋白尿评估。本系统评价的目的是提供蛋白尿作为肾肿瘤手术后肾功能损害和生存结果预测指标的证据。
使用三个搜索引擎(PubMed、Embase 和 Web of Science)从 2010 年 1 月到 2020 年 11 月进行了系统搜索。研究选择遵循 PRISMA 指南。筛选后,有 10 篇文章和摘要完全符合 PICOS 标准,被纳入本系统评价。
总的来说,分析了 11705 名接受部分肾切除术 (PN) 或根治性肾切除术 (RN) 的患者。当作为二项变量使用时,术前蛋白尿在 10%至 33%的患者中被检测到。依靠蛋白尿和估计肾小球滤过率 (eGFR) 评估肾功能,术前肾功能不全患者的比例高达 33%。此外,蛋白尿增加了 PN 和 RN 后长期肾功能不全的风险,以及术前有蛋白尿的患者行 PN 后发生术后急性肾损伤 (AKI) 的风险更高。在纳入的研究中,蛋白尿与糖尿病、肥胖、代谢综合征、高血压和心血管疾病有关。最后,蛋白尿是总死亡率的独立预测因素,但不是癌症特异性死亡率的独立预测因素。
蛋白尿为接受肾癌手术的患者提供了比估计肾小球滤过率 (eGFR) 更具预后能力的指标,支持在术前肾功能评估中引入蛋白尿。然而,需要进行设计良好的多中心前瞻性研究来证实这些结果,并为泌尿科医生提供高等级的临床实践推荐。